Literature DB >> 4924591

Measurement of portal pressure and its clinical application.

T B Reynolds, S Ito, S Iwatsuki.   

Abstract

Mesh:

Year:  1970        PMID: 4924591     DOI: 10.1016/s0002-9343(70)80131-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  20 in total

Review 1.  Clinical physiologic approach to the patient with portal hypertension.

Authors:  L Chiandussi
Journal:  Bull N Y Acad Med       Date:  1975-04

2.  Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.

Authors:  S Sugano; T Kawafune; T Okajima; K Ishii; M Watanabe; N Takamura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Renal effects of nadolol in cirrhosis.

Authors:  A Gatta; D Sacerdoti; C Merkel; L Caregaro; M Borsato; M Bolognesi; A Ruol
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

5.  Structural aspects of the liver in patients with biliary disease and portal hypertension.

Authors:  K Weinbren; N S Hadjis; L H Blumgart
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

6.  Differences in intrahepatic portal-systemic shunting in alcoholic and nonalcoholic liver disease as assessed by liver scan, portal pressure, and E. coli antibodies.

Authors:  D R Triger; T D Boyer; A G Redeker; T B Reynolds; A D Waxman
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

7.  Serum-ascites albumin gradients in nonalcoholic liver disease.

Authors:  M A Kajani; Y K Yoo; J A Alexander; J S Gavaler; R E Stauber; V J Dindzans; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

8.  Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; M Van Kuyk; C Melot; P Lejeune; H Ham; F Vertongen; R Naeije
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

Review 9.  Portal circulation and portal hypertension.

Authors:  S Sherlock
Journal:  Gut       Date:  1978-01       Impact factor: 23.059

10.  The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis.

Authors:  C Merkel; A Gatta; M Bolognesi; R Padrini; G F Finucci; P Angeli; A Ruol
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.